BIG1 Polyclonal Antibody, APC-Cy7 Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-12866R-APC-Cy7-100uL |
| Product Name | BIG1 Polyclonal Antibody, APC-Cy7 Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Mouse |
| Predicted Reactivity | Human, Rat, Dog, Cow, Sheep, Pig, Chicken |
| Specifications | |
| Conjugation | APC-Cy7 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human BIG1/ARFGEF1 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 10565 |
| Subcellular location | Cytoplasm, Nucleus, Cell membrane |
| Synonyms | ADPribosylation factor guanine nucleotide exchange factor 1brefeldin A inhibited; ARFGEF1; ARFGEP1; Brefeldin A inhibited GEP 1; Brefeldin A inhibited guanine nucleotide exchange protein 1; p200 ARF GEP1; p200 ARF guanine nucleotide exchange factor; BIG1_HUMAN. |
| Background | Guanine nucleotide-exchange proteins (GEPs) accelerate replacement of bound GDP with GTP and thereby activate ADP-ribosylation factors (ARFs), a family of guanine nucleotide-binding proteins that play an important role in intracellular vesicular trafficking. GEPs comprise two major families, large GEPs that are inhibited by brefeldin A (BFA), a protein that effects Golgi structure and a group of smaller GEPs that are insenstive to BFA. Two genes for GEPs found on human chromosomes 8 and 20 encode BFA sensitive GEPs designated BIG1 and BIG2. Both GEPS contain a sec7 domain that is responsible for their brefeldin inhibition and also their catalytic activity. In vivo, BIG1 and BIG2 exist in macromolecular complexes that move between the Golgi membranes and cytosol. BIG2 associates with PKA regulatory subunits, implying that BIG2 may act as an A kinase-anchoring protein (AKAP) that could coordinate the cAMP and ARF regulatory pathways. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is BIG1 Polyclonal Antibody, APC-Cy7 Conjugated (bs-12866R-APC-Cy7) validated for, and at what dilution?
bs-12866R-APC-Cy7 is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does BIG1 Polyclonal Antibody, APC-Cy7 Conjugated (bs-12866R-APC-Cy7) react with?
Tested reactivity: Mouse. Predicted reactivity (expected from sequence homology but not yet tested): Human, Rat, Dog, Cow, Sheep, Pig, Chicken.
How should bs-12866R-APC-Cy7 be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise BIG1 Polyclonal Antibody, APC-Cy7 Conjugated (bs-12866R-APC-Cy7)?
KLH conjugated synthetic peptide derived from human BIG1/ARFGEF1
What are the excitation and emission wavelengths of the APC-Cy7 conjugate (bs-12866R-APC-Cy7)?
APC-Cy7 on bs-12866R-APC-Cy7: excitation / emission 650nm/780nm.